Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694301 | 1.00 | MAPK1 (0.62) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL26597373 | 1.00 | MAPK1 (0.62) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL29535351 | 0.90 | MAPK1 (0.53) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL29535303 | 0.90 | MAPK1 (0.53) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL23631136 | 0.89 | MAPK1 (0.52) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL4322755 | 0.89 | MAPK1 (0.52) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL30694316 | 0.89 | MAPK1 (0.52) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL4258624 | 0.89 | MAPK1 (0.52) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL21067800 | 0.89 | MAPK1 (0.52) | MAPK1LGALS3NOD2ALDH1A1THRB | |
| SCHEMBL19521448 | 0.89 | MAPK1 (0.52) | MAPK1LGALS3NOD2ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366853-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | EXTHERA MEDICAL CORPORATION (US) | 2024-11-07 | — | — | US | disclosed |
| US-12090261-B2 | Method for modulating endothelial glycocalyx structure | EXTHERA MEDICAL CORPORATION (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240293555-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | CEDARS-SINAI MEDICAL CENTER | 2024-09-05 | — | — | US | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293555-A1 | CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES | CSGALNACT1, SLC2A8, FUT6 | MAPK1 4220/4885LGALS3 67/4885NOD2 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.